Press Releases

Date Title  
Toggle Summary Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO , Jan. 4, 2019 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted equity awards
Toggle Summary Audentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial Officer
SAN FRANCISCO , Jan. 3, 2019 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it has appointed Eric
Toggle Summary Audentes Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO , Jan. 2, 2019 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R.
Toggle Summary Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO , Dec. 7, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted equity awards
Toggle Summary Audentes Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO , Nov. 7, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it will participate in
Toggle Summary Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
- Completed Cohort 2 enrollment in ASPIRO, the Phase 1/2 clinical study of AT132 for the treatment of X-linked Myotubular Myopathy - Plan interactions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in Q4 2018 to discuss development plans and the potential
Toggle Summary Audentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as Chairman
Louis G. Lange, M.D., Ph.D. appointed as Lead Independent Director SAN FRANCISCO , Nov. 5, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious,
Toggle Summary Audentes Therapeutics to Release Third Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, November 6, 2018
SAN FRANCISCO , Oct. 30, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, will host a conference call and webcast to
Toggle Summary Audentes Therapeutics Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO , Oct. 10, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the pricing of its
Toggle Summary Audentes Therapeutics Announces Proposed Public Offering of Common Stock
SAN FRANCISCO , Oct. 9, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, announced today that it intends to offer